Spain: Ƙirƙirar Biotech - EIB tana ba da tallafin Euro miliyan 20 ga Sanifit don haɓaka jiyya don ƙididdigewar jijiyoyin jini.
- Bankin EU zai goyi bayan Sanifit na tushen Palma a cikin aikinsa don haɓaka mafita mai mahimmanci a cikin binciken ilimin halittu.
- Ayyukan bashi na kamfani yana goyan bayan Shirin Zuba Jari na Turai.
Bankin Zuba Jari na Turai (EIB) an saita shi don tallafawa haɓaka sabbin jiyya don ƙididdigewar jijiyoyi na ci gaba, yanki mai mahimmancin buƙatun likita wanda ba a yarda da shi ba a halin yanzu. Don wannan karshen, da EU Bankin zai ba da lamuni na Yuro miliyan 20 ga kamfanin samar da magunguna na Spain Sanifit, wanda ke haɓaka sabbin jiyya a cikin alamun cututtuka guda biyu masu alaƙa da ƙima.
EIB tana haɓaka kuɗi don wannan aikin bincike, haɓakawa da haɓakawa (RDI) ta hanyar aikin bashi tare da Shirin Zuba Jari na Turai tallafi, kayan aikin kuɗi da bankin EU ke amfani da shi don taimaka wa manyan kamfanoni a fannonin ƙirƙira. Tun lokacin da EIB ta ƙaddamar da shi a ƙarƙashin Tsarin Juncker a cikin 2016, wannan yunƙurin ya ba da gudummawar sama da Yuro biliyan 2 don ba da kuɗi don ayyuka a fannoni kamar robotics, basirar wucin gadi da biomedicine.
EIB za ta ba Sanifit kuɗi na dogon lokaci don fitar da ci gaban jiyya don ci gaba da rikice-rikice na jijiyoyi. Kamfanin, wanda aka kafa azaman juzu'i daga Jami'ar Balearic Islands, ya haɓaka SNF472, zaɓaɓɓen zaɓi da mai hanawa na hydroxyapatite (HAP) crystallisation, hanya ta gama gari ta ƙarshe wacce ke haifar da ƙima ta jijiyoyin jini.
A halin yanzu ana binciken SNF472 a cikin binciken Phase na 3 don kula da calciphylaxis, wata mummunar cuta da ba kasafai ba inda aka toshe ƙananan jijiyoyin jini a cikin fata da nama mai kitse saboda ƙima mai tsanani, wanda ke haifar da mutuwar kusan 55% na marasa lafiya a cikin shekarar farko. na ganewar asali. Gwajin mataki na 3 a cikin nuni na biyu, cututtukan jijiya na gefe, babban direban cuta da mutuwa a cikin marasa lafiya na ƙarshen zamani, za a ƙaddamar a cikin 2021.
Mataimakin shugaban EIB Emma Navarro, mai alhakin ayyukan Bankin a cikin Spain, ya haskaka"tasiri mai kyau na wannan aiki a kan ƙarfafa gasa na masana'antar nazarin halittu ta Turai, sashen da ke buƙatar babban jari da kuma daidaita hanyoyin samar da kuɗi. Mun yi farin cikin taimaka wa babban kamfani na Sipaniya don haɓaka sabbin jiyya don ƙididdigewar jijiyoyin jini waɗanda za su sami fa'idodi masu fa'ida ga lafiyar ɗan adam da walwala. Wannan yarjejeniya ta jaddada ƙudirin EIB na tallafawa ƙirƙira na Turai, wanda a yanzu ya fi kowane lokaci mahimmanci don haɓaka farfaɗo da tattalin arziki da samar da ayyukan yi."
Dokta Joan Perelló, Babban Jami'in Sanifit, sharhi: "Taimakon EIB yana wakiltar babban goyon bayan fasahar mu da yuwuwar sa don taimakawa marasa lafiya da ke fama da rashin ƙarfi da ke da alaƙa da haɓakar ƙwayar jijiyoyin jini. Wannan lokaci ne mai ban sha'awa ga Sanifit yayin da muke ci gaba da SNF472 ta hanyar asibitin, kuma wannan ƙarin saka hannun jari zai kasance mai amfani yayin da muke tattara bayanan ƙarshen matakin da ake buƙata don amincewa, da kuma isar da zaɓuɓɓukan jiyya ga mabuƙata.
Sanifit kamfani ne na asibiti-matakin biopharmaceutical wanda aka mayar da hankali kan jiyya don cututtukan ƙwayoyin cuta na jijiyoyin jini. Kamfanin ya fito ne daga Jami'ar Balearic Islands kuma yana da ofisoshi a ciki Spain da Amurka Kaddarar jagorar kamfanin, SNF472, ta sami nasarar kammala gwajin lokaci na 2 na nazarin ra'ayi a cikin calciphylaxis kuma ya nuna raguwa mai yawa a ci gaban calcification na jijiyoyin jini a cikin binciken Phase 2b tsakanin marasa lafiya na hemodialysis. Ana ci gaba da yin nazari mai mahimmanci na Phase 3 a cikin calciphylaxis a halin yanzu kuma ana gudanar da gwaji na Mataki na 3 a cikin Ciwon Jiji na Jiji a Ƙarshen Majinyacin Ƙarshen Ƙaddamar da marasa lafiya a cikin 2021. Sanifit ya tara kusan $ 130M, ciki har da 2019 Series D zagaye na $61.8M (€55.2) M) a tsakiyar 2019. Don ƙarin bayani ziyarci www.sanifit.com
